AnaptysBio (ANAB) Stock: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$48.53
-0.10 (-0.21%)
▼
5d:
-4.84%
30d:
-13.09%
90d:
-22.12%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
30d
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ANAB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ANAB shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$91.27
Based on 10.3% avg growth
INTRINSIC VALUE TODAY
$56.67
14.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $48.53, which is considered oversold relative to its 30-day fair value range of $51.41 to $57.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.6) compared to its historical average (11.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANAB is in a downtrend. The price is currently testing key support at $48.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ANAB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $87.25 (+79.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANAB is in a downtrend. The price is currently testing key support at $48.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ANAB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $87.25 (+79.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$51.41 -
$57.01
Company Quality Score
43/100
(HOLD)
Options IV Signal
42th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
59.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 42th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 79.8% below Wall St target ($87.25)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$51.41 -
$57.01
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$5.40
(11.1%)
Support & Resistance Levels
Support Level
$48.13
Resistance Level
$56.04
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.58
Wall Street Target
$87.25
(+79.8%)
Revenue Growth (YoY)
23.5%
Profit Margin
247.0%
Valuation Discount vs History
-4.7% cheaper
PE vs Historical
9.6 vs 11.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.7%
(market-implied from PE analysis)
1-Year Target
$46.25
(-5%)
2-Year Target
$44.08
(-9%)
3-Year Target
$42.00
(-13%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$48.69
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 16.5%)
$163.50
(+237%)
Base:
(SPY PE: 9.6, Growth: 16.5%)
$76.74
(+58%)
Bear:
(PE: 8.1, Growth: 16.5%)
$65.23
(+34%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.6 to 11.1
Stabilization Target:
$56.26
(+15.9%)
PE Expansion Potential:
+15.9%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 AM ET
Data refreshes hourly during market hours. Next update: 2:11 AM
Data refreshes hourly during market hours. Next update: 2:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 66 BUY |